世界の網膜疾患治療薬市場 – 2030 年までの業界動向と予測

網膜疾患治療薬市場の分析と規模

網膜は目の奥にある繊細な組織層で、光を感知して脳に画像を転送する役割を担っています。網膜疾患はどのような形であれ、この繊細な組織にダメージを与え、視力に影響を及ぼし、深刻な場合には失明につながる可能性があります。網膜疾患は遺伝性または加齢性で、視力の退行性変化を引き起こします。しかし、網膜検査は、遺伝性網膜疾患の遺伝子検査とともに、潜在的な疾患の診断の第一歩となります。

網膜疾患は、高齢者層と糖尿病患者において有病率と発症率が高く、そのため成人と糖尿病患者の人口が増加すると網膜疾患治療薬市場が拡大するでしょう。

データブリッジ市場調査は、2022年に125億7000万米ドルであった網膜疾患治療薬市場は、2030年までに256億9000万米ドルに達し、予測期間中に9.3％のCAGRを達成すると予測しています。網膜疾患治療薬市場の疾患セグメントでは、「黄斑変性」が有病率の高さから主流となっています。データブリッジ市場調査がまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

網膜疾患治療薬市場の範囲とセグメンテーション

Market Definition

Retinal diseases are a group of medical conditions that affect the retina, which is the light-sensitive tissue located at the back of the eye. These diseases can disrupt the normal functioning of the retina, leading to vision impairment or even blindness. Common retinal diseases include macular degeneration, diabetic retinopathy, retinal detachment, retinitis pigmentosa, and others. Therapeutics for retinal diseases aim to manage and treat these conditions to preserve or improve a patient's vision. Treatment approaches can vary depending on the specific disease and its severity but may include medications, laser therapy, surgery, and implantable devices among others.

Retinal Disease Therapeutics Market Dynamics

Drivers

• Aging Population

The aging population is more susceptible to retinal diseases, such as age-related macular degeneration (AMD). As the global population continues to age, the prevalence of retinal diseases is expected to increase, driving the demand for therapeutics

• Rising Incidence of Diabetes

Diabetic retinopathy is a common retinal disease associated with diabetes. The increasing incidence of diabetes worldwide is a significant driver of the retinal disease therapeutics market

Opportunities

• Medical Research and Development

Increased demand for retinal disease treatments will drive research and development efforts. This presents opportunities for pharmaceutical and biotech companies to innovate and develop new drugs and therapies for retinal diseases

• Technological Advancements

As the market grows, there will be a greater need for advanced diagnostic and treatment technologies. This creates opportunities for companies involved in developing cutting-edge medical devices and imaging technologies for retinal diseases

Restraints/Challenges

• High Cost of Treatment

The cost of some retinal disease treatments, including anti-VEGF drugs and surgical interventions, can be prohibitively expensive. This cost burden can limit access to these therapies for some patients

• Limited Efficacy of Current Treatments

While significant progress has been made, some retinal diseases still lack highly effective treatments. For instance, advanced stages of certain diseases such as retinitis pigmentosa may have limited therapeutic options

This retinal disease therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Retinal disease therapeutics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

• In October 2022, in a 600% million deal, Boehringer Ingelheim targets Surrozen’s preclinical disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease

Global Retinal Disease Therapeutics Market Scope

The retinal disease therapeutics Market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disorder

• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Disorder Type

• Genetic
• Age Related

Treatment Techniques

• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Route of Administration

• Oral
• Topical
• Intravitreal
• Others

End-Users

• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Regional Analysis/Insights

The retinal disease therapeutics market is analyzed and market size insights and trends are provided by disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.

The countries covered in the retinal disease therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with the majority of population have insurance cover to claim this type of expensive treatment.

Asia-Pacific region is expected to record the fastest growth during the forecast period due to increasing patient pool, improving public and private reimbursement infrastructure, and constant development of healthcare facilities.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis

網膜疾患治療薬市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、網膜疾患治療薬市場に関連する会社の焦点にのみ関連しています。

網膜疾患治療薬市場で活動している主要企業は次のとおりです。

• 参天製薬株式会社（日本）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• Sentis Pharma Pvt Ltd.（インド）
• F. ホフマン・ラ・ロシュ社（スイス）
• ジョンソン・エンド・ジョンソン・サービス社（米国）
• ノバルティスAG（スイス）
• アッヴィ（米国）
• リジェネロン・ファーマシューティカルズ社（米国）
• アコーン（米国）
• ミトテックSA（ロシア）
• 窪田製薬ホールディングス株式会社（日本）
• グレイバグビジョン株式会社（米国）
• サン・ファーマシューティカル・インダストリーズ（インド）
• 大塚製薬株式会社（日本）
• 千寿製薬株式会社（日本）
• ヴァレント・ファーマシューティカルズ・ノース・アメリカ LLC (米国)
• ジェネンテック社（米国）
• オキュラーセラピューティクス（米国）
• テバ製薬工業株式会社（イスラエル）
• カラ・ファーマシューティカルズ（米国）
• アイヴェンシス（フランス）
• アルデイラ・セラピューティクス社（米国）

SKU-60084